Abstract: Disclosed is an insect repulsion and/or barrier system (10) and a method for repelling insects (2) and/or for preventing insects (2) from passing through a defined opening (12) or surface (9). The barrier system (10) is equipped with devices (16) for preventing insects from passing through an opening (12) or for repelling insects when approaching the opening (12) and/or the devices (16). The devices (16) have at least two electrodes (18), whereby different electrical potentials are applied to or can be applied to the at least two electrodes (18). The at least two electrodes (18) are arranged within or on the edge of or outside the opening such that an electrical field (28) is formed between the at least two electrodes (18). The electrical field (28) rejects and/or repels insects approaching the electrical field (28) or prevents insects approaching the electrical field (28) from passing through the opening (12).

Abstract: Disclosed is an insect repulsion and/or barrier system (10) and a method for repelling insects (2) and/or for preventing insects (2) from passing through a defined opening (12) or surface (9). The barrier system (10) is equipped with devices (16) for preventing insects from passing through an opening (12) or for repelling insects when approaching the opening (12) and/or the devices (16). The devices (16) have at least two electrodes (18), whereby different electrical potentials are applied to or can be applied to the at least two electrodes (18). The at least two electrodes (18) are arranged within or on the edge of or outside the opening such that an electrical field (28) is formed between the at least two electrodes (18). The electrical field (28) rejects and/or repels insects approaching the electrical field (28) or prevents insects approaching the electrical field (28) from passing through the opening (12).

Abstract: The present subject matter relates to novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one represented by Formula II: , pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Abstract: The present invention relates to an improved process for preparation of Voriconazole and Voriconazole (1R)-(?)-10-camphorsulfonate.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms. In particular, the present subject matter relates to the specific crystalline Forms I, II, III, IV, V, and VI of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one.

Abstract: Novel crystalline forms of (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2 -hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one, pharmaceutical compositions containing these crystalline forms, methods of using these crystalline forms for treating and/or preventing various microbial and/or fungal infections or disorders, and processes for obtaining these crystalline forms.

Abstract: The invention relates to new polymorphic forms of olopatadine hydrochloride, designated herein as olopatadine hydrochloride Forms A and B, and methods of preparing, purifying and treating them.

Abstract: The invention relates to polymorphic crystalline forms of aripiprazole, synthetic processes for their preparation and pharmaceutical compositions containing the same. These crystalline forms of aripiprazole can be readily milled and can be easily combined with various pharmaceutical adjuvants without effecting changes to their crystalline structure when, for example, pressed into tablet or capsule form.

Abstract: The present invention relates to an improved process for preparation of Voriconazole and Voriconazole (1R)-(?)-10-camphorsulfonate.

Abstract: The present invention relates to a novel process for the preparation of montelukast sodium, a compound of Formula (1b) and precursors thereof. The invention further concerns the free acid of this compound in crystalline form, obtainable for the first time by the new process.